Bladder Cancer COE

ANTICIPATE II Trial: APL-1202 and Tislelizumab for Neoadjuvant Bladder Cancer Treatment - Matthew Galsky

Details
Sam Chang converses with Matthew Galsky about the ANTICIPATE II trial, examining the combination of APL-1202 (nitroxoline salt) and tislelizumab in treating muscle-invasive bladder cancer. Dr. Galsky discusses APL-1202's journey from an antibiotic with noted anti-cancer properties to a promising cancer treatment due to its immunogenic cell death induction and potential synergy with PD-1 inhibitors...

Comprehensive Genetic Profiling May Optimize Targeted Therapy Selection for FGFR3-Mutated Urothelial Carcinoma Patients - Michael Basin

Details
Michael Basin presents an analysis on FGFR alterations and the genomic landscape differences between upper and lower tract urothelial carcinoma. Utilizing data from the extensive Foundation Medicine database, which includes around 10,000 bladder cancer patients, Dr. Basin's study focuses on the subset with FGFR mutations. The research reveals that lower tract tumors possess more genomic co-drivers...

The Economic Impact of Cystectomy vs Trimodal Bladder Therapy - Stephen Williams

Details
Zachary Klaassen and Stephen Williams delve into the economic and treatment implications of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Dr. Williams, with a collaborative team spanning medical oncology to economic experts, has spent over a decade exploring these treatment pathways, revealing significant cost differences and outcomes through extensive research, in...

BCG Shortage: What’s on the Horizon to Replace? - Joshua Meeks

Details
Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability. The d...

PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson

Details
Ashish Kamat and Mark Tyson discuss the currently enrolling PIVOT-006 study. Dr. Tyson discusses cretostimogene grenadenorepvec, a conditionally replicating oncolytic adenovirus designed for cancer cell destruction and immunotherapeutic effects. Highlighting four pivotal studies demonstrating the agent's efficacy, especially in BCG unresponsive populations, Dr. Tyson outlines the development of in...

Establishing Nadofaragene Firadenovec in a Large Urology Practice - Daniel Canter

Details
Ashish Kamat and Daniel Canter discuss the role of nadofaragene firadenovec in the treatment of non muscle-invasive bladder cancer. Dr. Canter, drawing from his firsthand experience in Phase 1, 2, and 3 trials, highlights the therapy's tolerability and its efficacy, particularly noting its superior administration schedule compared to BCG. With a focus on real-world application, they explore the si...

The Microbiome's Impact on the Immunotherapy of Genitourinary Cancers - Sumanta Kumar Pal

Details
Ashish Kamat and Professor Sumanta (Monty) Pal discuss the microbiome's influence on genitourinary cancers and immunotherapy. Highlighting foundational research, Dr. Pal explains how the gut microbiome composition affects immunotherapy outcomes, with variability in bacterial species linked to treatment responses. He emphasizes the detrimental impact of antibiotics on immunotherapy efficacy and int...

Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC - Stephen Boorjian

Details
Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary endpoint...

Bladder Cancer: En Bloc Resection Technique Shows Promise - David D'Andrea

Details
Ashish Kamat welcomes David D'Andrea to discuss the eBLOC trial, focusing on en-bloc versus conventional resection of bladder tumors. He highlights the historical context of TURB (Transurethral Resection of Bladder Tumor) and its limited evolution over the years. The eBLOC trial, designed to compare en-bloc and conventional TURB, aimed to improve the quality of resection, crucial for accurate stag...

Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? - Amanda Myers

Details
Amanda Myers presents a comprehensive review on lymph node dissection in GU cancers as of 2023. She emphasizes its critical role in surgical urologic care for accurate staging and detecting micrometastases. The review, based on systematic research from 2014 to 2023, covers bladder, upper tract, kidney, prostate, and penile cancers. Key findings include the recommendation of standard pelvic lymph n...